Roche Holding AG (SWX:ROP)
332.40
-1.40 (-0.42%)
Jul 22, 2026, 5:31 PM CET
Roche Holding AG Revenue
In the year 2025, Roche Holding AG had annual revenue of 63.36B CHF with 1.54% growth. Roche Holding AG had revenue of 31.51B in the half year ending December 31, 2025, with 5.64% growth.
Revenue
63.36B
Revenue Growth
+1.54%
P/S Ratio
4.20
Revenue / Employee
613.62K
Employees
103,249
Market Cap
265.96B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 63.36B | 961.00M | 1.54% |
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | 63.75B | 4.25B | 7.15% |
| Dec 31, 2018 | 59.50B | 3.75B | 6.73% |
| Dec 31, 2017 | 55.75B | 3.11B | 5.91% |
| Dec 31, 2016 | 52.64B | 2.23B | 4.43% |
| Dec 31, 2015 | 50.40B | 537.00M | 1.08% |
| Dec 31, 2014 | 49.87B | 1.25B | 2.58% |
| Dec 31, 2013 | 48.61B | 1.17B | 2.46% |
| Dec 31, 2012 | 47.44B | 3.33B | 7.55% |
| Dec 31, 2011 | 44.11B | -5.05B | -10.28% |
| Dec 31, 2010 | 49.17B | -1.98B | -3.88% |
| Dec 31, 2009 | 51.15B | 3.25B | 6.78% |
| Dec 31, 2008 | 47.90B | -472.00M | -0.98% |
| Dec 31, 2007 | 48.38B | 4.94B | 11.38% |
| Dec 31, 2006 | 43.43B | 6.47B | 17.52% |
| Dec 31, 2005 | 36.96B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novartis AG | 45.81B |
| Sandoz Group AG | 8.85B |
| Alcon | 8.53B |
| Lonza Group AG | 6.53B |
| Galderma Group AG | 4.16B |
| Galenica AG | 4.15B |
| Sonova Holding AG | 3.61B |
| Straumann Holding AG | 2.61B |
Roche Holding AG News
- 3 hours ago - Roche showcases intelligent lab solutions and high-precision instruments at ADLM 2026 to help laboratories address workforce and workflow challenges - PRNewsWire
- 8 hours ago - MaxCyte Signs Multi-Platform Technology License Partnership With Genentech - Nasdaq
- 11 hours ago - Nurix Closes Roche Collaboration After HSR Clearance For Bexobrutide, Secures $700 Million Upfront - Nasdaq
- 1 day ago - MaxCyte enters technology license partnership with Genentech - TheFly
- 1 day ago - Roche Appoints Dan Malarek CEO Of Diagnostics North America; Names U.S. Commercial Chief - Nasdaq
- 2 days ago - Roche names Dan Malarek as President and CEO of Roche Diagnostics North America - TheFly
- 2 days ago - Roche Appoints Dan Malarek as President and CEO of Roche Diagnostics North America - PRNewsWire
- 6 days ago - Roche (RHHBY) Receives FDA Priority Review for Gazyva Kidney Therapy Expansion - GuruFocus